Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase
Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/jcpt/5621631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 05.08.2026. Verfasst von Danyun Li und 4 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Provincial Health Technology Project, Fujian Medical University.
Abstract (Originalsprache)
Background
Metabolic reprogramming contributes to ovarian cancer progression and therapeutic resistance, and glutamine utilization plays a critical role in supporting tumor growth and maintaining redox homeostasis. Cardamonin, a naturally occurring chalcone compound, has demonstrated antitumor activity in several malignancies; however, its effects on glutamine metabolism in ovarian cancer remain unclear.
Methods
Human ovarian cancer SKOV3 and A2780 cells were cultured under glutamine‐sufficient and glutamine‐deprived conditions and treated with cardamonin to evaluate its antiproliferative effects. Cell viability was assessed by CCK‐8 assay. Apoptosis and intracellular reactive oxygen species (ROS) levels were measured by flow cytometry. The expression of glutaminase and mTORC1 pathway‐related proteins was examined by western blotting. In addition, Raptor‐deficient SKOV3 cells were used to further investigate the underlying mechanism.
Results
Cardamonin significantly inhibited ovarian cancer cell proliferation, with more pronounced suppressive effects observed under glutamine‐rich conditions. In addition, cardamonin increased apoptotic cell populations and promoted ROS accumulation in SKOV3 cells. Western blot analysis demonstrated that cardamonin decreased glutaminase expression and reduced phosphorylation of S6K1. Similar suppression of glutaminase expression was observed following rapamycin treatment. Furthermore, Raptor deficiency reduced glutaminase expression and attenuated the inhibitory effects of cardamonin on glutaminase expression and S6K1 phosphorylation.
Conclusions
These findings suggest that cardamonin impairs glutamine‐dependent ovarian cancer cell growth through inhibiting glutaminase expression, which is associated with blockade of the mTORC1 signaling pathway. Collectively, the present study supports glutamine metabolism as a potential therapeutic target of cardamonin in ovarian cancer.
Förderung
- Fujian Provincial Health Technology Project
- Fujian Medical University
Zitieren
APA
Li, D., Niu, P., Zhu, Y., Chen, H., & Ding, Q. (2026). Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/5621631
Vancouver
Li D, Niu P, Zhu Y, Chen H, Ding Q. Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/5621631
BibTeX
@article{Li2026,
author = {Li, Danyun and Niu, Peiguang and Zhu, Yanting and Chen, Huajiao and Ding, Qiuhua},
title = {Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jcpt/5621631}
}
EUVIMED